Study of CYP2C9 gene polymorphism in women taking valproate
https://doi.org/10.1234/XXXX-XXXX-2015-10-36-41
Abstract
This research objective was to explore the frequencies of polymorphic allelic variants of CYP2C9 gene, which encodes 2C9 isoenzyme of P450 liver cytochrome, in women of childbearing age, and the association of carriage of CYP2C9*2 and CYP2C9*3 polymorphic variants with valproic acid (VA) level and valproate-induced side effects. Methods: we examined DNA of 148/199 (74.4%) female patients taking valproate. Results: heterozygous carriage of CYP2C9*2 allele was found in 12.2% cases, heterozygous carriage of CYP2C9*3 found in 18.9%, and the compound heterozygote (genotype CYP2C9*2/*3) was diagnosed in 1.4% cases. Incidence of valproic acid cumulation in the compound heterozygote CYP2C9*2/*3 female carriers was 8 times higher than that in homozygous female carriers of CYP2C9*1 ‘wild’ allele; and this incidence in heterozygous female carriers of CYP2C9*2 and CYP2C9*3 was, respectively, 2.6 times and 3 times higher than that in the homozygous carriers of CYP2C9*1.
About the Authors
D. V. Dmitrenko
Krasnoyarsk State Medical University named after prof. V.F. Voyno-Yasenetsky, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. A. Shnayder
Krasnoyarsk State Medical University named after prof. V.F. Voyno-Yasenetsky, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Каримов Х.Я., Азимова С.Б., Бобоев К.Т. Анализ генотипических вариантов полиморфизма гена CYP2C9 в узбекской популяции // Междунар. мед. журн. - 2012. - № 4. - С. 106-109.
2. Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. - М.: Реафарм, 2004. - 144 с.
3. Михеева Ю.А., Кропачева Е.С., Игнатьев И.В. и др. Полиморфизм гена цитохрома Р450 2С9 (CYP2C9) и безопасность терапии варфарином // Кардиология. - 2008. - № 48. - С. 52-57.
4. Обжерина А.Ю., Сычев Д.А., Муравьев Ю.В. и др. Полиморфизм CYP2C9: новый фактор риска развития желудочно-кишечных осложнений при применении нестероидных противоспалительных препаратов // Клин. фармакология и фармакоэкономика. - 2009. - № 5. - С. 20-25.
5. Сироткина О.В., Улитина А.С., Тараскина А.Е. и др. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином // Рос. кардиол. журн. - 2004. - № 6. - С. 47-51.
6. Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Клиническая фармакогенетика. - М.: Гэотар-Медиа, 2007. - 230 с.
7. Шнайдер Н.А., Сычев Д.А., Пилюгина М.С., Дмитренко Д.В., Бочанова Е.Н., Шаповалова Е.А. Значение фармакогенетики вальпроевой кислоты в индивидуальном подходе к лечению страдающих эпилепсией женщин фертильного возраста // Журнал неврологии и психиатрии им. С.С. Корсакова. Выпуск 2 Эпилепсия. - 2011. - Т. 111, №5. - С. 31-37.
8. Aynacioglu A.S., Brockmoller J., Bauer S. et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin // Br. J. Clin. Pharmacol. - 1999. - Vol. 483. - P. 409-415.
9. Azarpira N., Namazi S., Hendijani F. et al. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran // Pharmacol. Rep. - 2010. - Vol. 62. - P. 740-746.
10. Bae J.-W., Kim H.-K., Kim J.-H. et al. Allele and genotype frequencies of CYP2C9 in a Korean population // Br. J. Clin. Pharmacol. - 2005. - Vol. 60. - P. 18-422. 159.
11. Bozina N., Granic P., Lalic Z. et al. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population // Croat. Med. J. - 2003. - Vol. 44, № 4. - P. 425-428.
12. Brusturean-Bota E., Trifa A.P., Coadа C.A. et al. Impact of CYP2C9 genetic polymorphisms on valproate dosage, plasma concentrations of valproate and clinical response to valproate // Hum. Veterinary Med. Int. J. Bioflux Soc. - 2013. - Vol. 5, № 3. - P. 94-98.
13. Dmitrenko D., Shnayder N., Muravieva A., Govorina Y. The Influence of CYP2C9 genetic polimorphisms on the plasma concentrations of valproic acid concentration in women of childbearing age with epilepsy // LATDMCT European Conference «Therapeutic Drug Monitoring Personalised Pharmakotherapy»: Book of abstracts and Congress Programme. - Prague, Proxima. - 2014. - P. 59-60.
14. Ho P.C., Abbott F.S., Zanger U.M. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes // Pharmacogenomics J. - 2003. - Vol. 3, № 6. - P. 335-342.
15. Kasperaviciute D., Sisodiya S.M. Epilepsy pharmacogenetics // Pharmacogenomics. - 2009. - Vol. 10. - P. 817-836.
16. Kiang T.K., Ho P.C., Anari M.R. et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/CYP2C9*1 genotype // Toxicol. Sci. - 2006. - Vol. 94, № 2. - P. 261-271.
17. Kumari R., Lakhan R., Garg R.K. et al. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population // Indian J. Human. Gen. - 2011. - Vol. 17, № 4. - P. 32-40.
18. Rosemary J., Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance // Curr. Clin. Pharmacol. - 2007. - Vol. 2, № 1. - P. 93-109.
19. Saruwatari J., Ishitsu T., Nakagawa K. Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy // Pharmaceuticals. - 2010. - Vol. 3. - P. 2709-2732.
20. Scordo M.G., Aklillu E., Yasar U. et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population // Br. J. Clin. Pharmacol. - 2001. - Vol. 52, № 4. - P. 447-450.
21. Seng K.C., Gin G.G., Sangkar J.V. et al. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia // Asia Pacific J. Mol. Biol. Biotech. - 2003. - Vоl. 1. - P. 83-91.
22. Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications // Clin. Pharmacokinet. - 2001. - Vol. 40. - P. 587-603.
23. Tan L., Yu J.T., Sun Y.P. et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients // Clin. Neurol. Neurosurg. - 2010. - Vol. 112, № 4. - P. 320-323.
Review
For citations:
Dmitrenko D.V., Shnayder N.A. Study of CYP2C9 gene polymorphism in women taking valproate. Medical Genetics. 2015;14(10):36-41. (In Russ.) https://doi.org/10.1234/XXXX-XXXX-2015-10-36-41
Views:
593
Email this article 